Clinical Trials Browser

Phase 2 × Hematologic Neoplasms × itacitinib × Clear all

NCT05660421 2024-10-31

Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Phase 2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT04127721 2020-10-29

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Phase 2 Withdrawn

Other hematologic neoplasm

Hematologic Diseases, Hematologic Neoplasms